AG2R LA Mondiale Gestion D Actifs Makes New $1.91 Million Investment in Edwards Lifesciences Corporation $EW

AG2R LA Mondiale Gestion D Actifs acquired a new position in shares of Edwards Lifesciences Corporation (NYSE:EW) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 24,437 shares of the medical research company’s stock, valued at approximately $1,911,000.

A number of other large investors also recently made changes to their positions in the stock. Jennison Associates LLC lifted its stake in shares of Edwards Lifesciences by 34.3% in the 1st quarter. Jennison Associates LLC now owns 10,086,033 shares of the medical research company’s stock valued at $731,036,000 after purchasing an additional 2,576,383 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of Edwards Lifesciences by 4.1% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 6,783,568 shares of the medical research company’s stock valued at $491,673,000 after purchasing an additional 264,311 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in shares of Edwards Lifesciences by 8.5% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 6,519,257 shares of the medical research company’s stock valued at $482,621,000 after purchasing an additional 513,468 shares during the period. Nuveen LLC acquired a new position in shares of Edwards Lifesciences in the 1st quarter valued at $330,881,000. Finally, Invesco Ltd. lifted its stake in shares of Edwards Lifesciences by 2.6% in the 1st quarter. Invesco Ltd. now owns 4,287,712 shares of the medical research company’s stock valued at $310,773,000 after purchasing an additional 107,241 shares during the period. Institutional investors and hedge funds own 79.46% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on EW. Dbs Bank raised Edwards Lifesciences to a “hold” rating in a research note on Monday, June 2nd. JPMorgan Chase & Co. increased their price target on Edwards Lifesciences from $80.00 to $85.00 and gave the company a “neutral” rating in a research note on Friday, July 25th. Deutsche Bank Aktiengesellschaft increased their price target on Edwards Lifesciences from $85.00 to $94.00 and gave the company a “buy” rating in a research note on Friday, July 25th. Stifel Nicolaus raised their price objective on Edwards Lifesciences from $90.00 to $95.00 and gave the stock a “buy” rating in a research note on Friday, July 25th. Finally, Wall Street Zen downgraded Edwards Lifesciences from a “strong-buy” rating to a “buy” rating in a research note on Saturday. Three investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $86.26.

Edwards Lifesciences Stock Performance

Shares of Edwards Lifesciences stock opened at $77.50 on Friday. The company has a market capitalization of $45.50 billion, a PE ratio of 11.15, a PEG ratio of 3.76 and a beta of 1.07. Edwards Lifesciences Corporation has a 12 month low of $64.00 and a 12 month high of $83.00. The company has a current ratio of 4.68, a quick ratio of 3.87 and a debt-to-equity ratio of 0.06. The stock’s fifty day simple moving average is $78.92 and its 200 day simple moving average is $75.39.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Thursday, July 24th. The medical research company reported $0.67 EPS for the quarter, topping the consensus estimate of $0.62 by $0.05. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The business had revenue of $1.53 billion for the quarter, compared to the consensus estimate of $1.49 billion. During the same quarter last year, the business posted $0.70 EPS. The firm’s revenue was up 11.9% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. On average, research analysts predict that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Insider Activity

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 4,114 shares of the business’s stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $79.46, for a total value of $326,898.44. Following the sale, the vice president owned 22,002 shares in the company, valued at approximately $1,748,278.92. The trade was a 15.75% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Larry L. Wood sold 8,950 shares of the business’s stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $78.06, for a total value of $698,637.00. Following the completion of the sale, the insider owned 206,900 shares in the company, valued at $16,150,614. The trade was a 4.15% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 22,014 shares of company stock worth $1,698,844 in the last three months. Company insiders own 1.29% of the company’s stock.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.